Innovent Biologics, Inc. announces the licensing deal expansion with Synaffix B.V., a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index. The expanded deal builds on a previous agreement signed in June 2021, under which Innovent is granted to deploy Synaffix's ADC technologies on a target-specific, non-exclusive basis, including GlycoConnect(R), HydraSpace(R) and one of its toxSYN(R) linker-payloads, for a therapeutic molecule (Innovent R&D code: IBI343, a CLDN18.2 ADC) which has advanced to Phase 1 clinical development. Under the terms of the expanded agreement, Innovent will focus the development of at least one new ADC candidate, building on Synaffix's ADC technology to enable best-in-class efficacy and tolerability for ADCs.

Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates. Synaffix is eligible to receive an upfront payment plus potential milestone payments and royalties on commercial sales for each licensed target.